Frühe und schwer verlaufende hämolytische Erkrankung des Fetus und Neugeborenen

Beate Mayer; Alexander Weichert

doi:10.1055/a-0972-6307

Transfusionsmedizin, Inhaltsverzeichnis

Transfusionsmedizin 2020; 10(02): 89-93
DOI: 10.1055/a-0972-6307

Kasuistik

Georg Thieme Verlag KG Stuttgart · New York

Frühe und schwer verlaufende hämolytische Erkrankung des Fetus und Neugeborenen

Early and Severe Hemolytic Disease of the Fetus and Newborn

Beate Mayer

¹Institut für Transfusionsmedizin, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health

,

Alexander Weichert

²Klinik für Geburtsmedizin, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health

› Institutsangaben

Abstract

Zusammenfassung

Eine schwere Alloimmunisierung der Schwangeren gegen erythrozytäre Blutgruppenmerkmale kann insbesondere bei Antikörpern der Spezifität Anti-K bereits vor der 20. Schwangerschaftswoche zu einer fetalen Anämie führen. Wir berichten über eine 37-jährige Schwangere (Gravida 6, Para 5) mit bekanntem Anti-K. In der Vorgeschichte kam es aufgrund einer K-Inkompatibilität in der 4. Schwangerschaft in der 34. Schwangerschaftswoche (SSW) zu einem Hydrops fetalis und in der 5. Schwangerschaft in der 22. SSW zu einem intrauterinen Fruchttod. Mittels eines nicht invasiven Pränataltests (NIPT) wurde in der aktuellen Schwangerschaft erneut ein K-positiver Fetus bestätigt. Aufgrund der Vorgeschichte erfolgte eine prophylaktische hochdosierte i. v. Immunglobulingabe (IVIG) (1 g/kgKG/Woche) ab der 14. SSW. In der 29 + 1 SSW war bei beginnender fetaler Anämie eine intrauterine Transfusion (IUT) erforderlich. Der weitere Schwangerschaftsverlauf gestaltete sich unter Fortführung der wöchentlichen IVIG-Therapie unauffällig. Das Kind kam in der 40 + 2 SSW durch Spontangeburt zur Welt. Bei positivem direktem Coombs-Test ließ sich im Eluat das mütterliche Anti-K nachweisen. Postpartal kam es bei dem Neugeborenen nur zu einem leichten Abfall der Hämoglobinkonzentration von 11,7 auf 9,5 g/dl. Eine Therapie war nicht erforderlich.

Abstract

Severe alloimmunization of pregnant women against antigens on red blood cells (RBC) can lead to fetal anemia even before the 20th week of gestation, especially if anti-K antibodies are present. We report of a 37-year-old pregnant woman (G₆P₅) with known anti-K. She had a past history of fetal hydrops at 34th week of gestation in the 4th pregnancy and an intrauterine fetal demise at the 22nd gestational week in her 5th pregnancy caused by K-incompatibility, respectively. Using non-invasive prenatal testing (NIPT), a K-positive fetus was confirmed in the current pregnancy. In view of the previous history, prophylactic high-dose i. v. immunoglobulin (IVIG) (1 g/kg bw/week) was administered from the 14th week of gestation onwards. Due to fetal anemia, an intrauterine transfusion (IUT) was necessary at gestational week 29 + 1. The further course of the pregnancy was inconspicuous, while continuing the weekly IVIG therapy. The child was delivered at 40 + 2 weeks of gestation by vaginal delivery. The direct Coombs test was positive, and maternal anti-K could be eluted from the newbornsʼ RBC. Post partum there was only a slight decrease in hemoglobin concentration from 11.7 g/dl to 9.5 g/dl with no therapy necessary.

Schlüsselwörter

hochdosierte intravenöse Immunglobulingabe - therapeutische Plasmapherese - erythrozytäre Alloimmunisierung in der Schwangerschaft - intrauteriner Kindstod

Key words

high-dose intravenous immunoglobulins - therapeutic plasmapheresis - RBC alloimmunization in pregnancy - fetal loss

Volltext

Referenzen

Literatur
1 Heddle NM, Klama L, Frassetto R. et al. A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy. Transfusion 1993; 33: 217-220
2 Gottvall T, Filbey D. Alloimmunization in pregnancy during the years 1992–2005 in the central west region of Sweden. Acta Obstet Gynecol Scand 2008; 87: 843-848
3 Koelewijn JM, Vrijkotte TG, van der Schoot CE. et al. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008; 48: 941-952
4 Markham KB, Rossi KQ, Nagaraja HN. et al. Hemolytic disease of the fetus and newborn due to multiple maternal antibodies. Am J Obstet Gynecol 2015; 213: 68.e1-68.e5
5 Sürücü G, Mayer B, Märzacker A. et al. Harmless Pregnancy-Induced Warm Autoantibodies to Red Blood Cells. Transfus Med Hemother 2015; 42: 325-327
6 Chatziantoniou V, Heeney N, Maggs T. et al. A descriptive single-centre experience of the management and outcome of maternal alloantibodies in pregnancy. Transfus Med 2017; 27: 275-285
7 Moise KJ, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012; 120: 1132-1139
8 de Haas M, Thurik FF, Koelewijn JM. et al. Haemolytic disease of the fetus and newborn. Vox Sang 2015; 109: 99-113
9 Hackney DN, Knudtson EJ, Rossi KQ. et al. Management of pregnancies complicated by anti-c isoimmunization. Obstet Gynecol 2004; 103: 24-30
10 Joy SD, Rossi KQ, Krugh D. et al. Management of pregnancies complicated by anti-E alloimmunization. Obstet Gynecol 2005; 105: 24-28
11 Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med 2008; 13: 207-214
12 Slootweg YM, Lindenburg IT, Koelewijn JM. et al. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. Am J Obstet Gynecol 2018; 219: 393.e1-393.e8
13 Oepkes D, Brand R, Vandenbussche FP. et al. The use of ultrasonography and Doppler in the prediction of fetal haemolytic anaemia: a multivariate analysis. Br J Obstet Gynaecol 1994; 101: 680-684
14 Mari G, Deter RL, Carpenter RL. et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342: 9-14
15 Yinon Y, Visser J, Kelly EN. et al. Early intrauterine transfusion in severe red blood cell alloimmunization. Ultrasound Obstet Gynecol 2010; 36: 601-606
16 Canlorbe G, Macé G, Cortey A. et al. Management of very early fetal anemia resulting from red-cell alloimmunization before 20 weeks of gestation. Obstet Gynecol 2011; 118: 1323-1329
17 Lindenburg IT, van Kamp IL, van Zwet EW. et al. Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation. BJOG 2013; 120: 847-852
18 Axt-Fliedner R, Wienzek-Lischka S, Sachs U. et al. Hämolytische Erkrankung des Fetus und Neugeborenen. Teil 1: Ätiologie, Pathogenese, Diagnostik und Therapie in der Schwangerschaft. Transfusionsmedizin 2018; 8: 95-110
19 Poissonnier MH, Picone O, Brossard Y. et al. Intravenous fetal exchange transfusion before 22 weeks of gestation in early and severe red-cell fetomaternal alloimmunization. Fetal Diagn Ther 2003; 18: 467-471
20 Zwiers C, Lindenburg IT, Klumper FJ. et al. Complications of intrauterine intravascular blood transfusions: lessons learned after 1678 procedures. Ultrasound Obstet Gynecol 2017; 50: 180-186
21 Rewald E, Suringar F. Substitutive-inhibitory gamma globulin therapy as prevention of stillbirth in Rh-incompatibility. Acta Haematol 1965; 34: 209-214
22 Berlin G, Selbing A, Ryden G. Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin. Lancet 1985; 1: 1153
23 Chitkara U, Bussel J, Alvarez M. et al. High-dose intravenous gamma globulin: does it have a role in the treatment of severe erythroblastosis fetalis?. Obstet Gynecol 1990; 76: 703-708
24 Margulies M, Voto LS, Mathet E. High-dose intravenous IgG for the treatment of severe rhesus alloimmunization. Vox Sang 1991; 61: 181-189
25 Dooren MC, van Kamp IL, Scherpenisse JW. et al. No beneficial effect of low-dose fetal intravenous gammaglobulin administration in combination with intravascular transfusions in severe Rh D haemolytic disease. Vox Sang 1994; 66: 253-257
26 Ulm B, Kirchner L, Svolba G. et al. Immunoglobulin administration to fetuses with anemia due to alloimmunization to D. Transfusion 1999; 39: 1235-1238
27 Kriplani A, Malhotra Singh B, Mandal K. Fetal intravenous immunoglobulin therapy in rhesus hemolytic disease. Gynecol Obstet Invest 2007; 63: 176-180
28 Anderson D, Ali K, Blanchette V. et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 2007; 21 (2 Suppl. 1): S9-S56
29 Mayer B, Hinkson L, Hillebrand W. et al. Efficacy of Antenatal Intravenous Immunoglobulin Treatment in Pregnancies at High Risk due to Alloimmunization to Red Blood Cells. Transfus Med Hemother 2018; 45: 429-436
30 Wong KS, Connan K, Rowlands S. et al. Antenatal immunoglobulin for fetal red blood cell alloimmunization. Cochrane Database Syst Rev 2013; (05) CD008267
31 Palmeira P, Quinello C, Silveira-Lessa AL. et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012: 985646
32 Zwiers C, van der Bom JG, van Kamp IL. et al. Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol 2018; 219: 291.e1-291.e9
33 Porter TF, Silver RM, Jackson GM. et al. Intravenous immune globulin in the management of severe Rh D hemolytic disease. Obstet Gynecol Surv 1997; 52: 193-197
34 de la Cámara C, Arrieta R, González A. et al. High-dose intravenous immunoglobulin as the sole prenatal treatment for severe Rh immunization. N Engl J Med 1988; 318: 519-520
35 Gottvall T, Selbing A. Alloimmunization during pregnancy treated with high dose intravenous immunoglobulin. Effects on fetal hemoglobin concentration and anti-D concentrations in the mother and fetus. Acta Obstet Gynecol Scand 1995; 74: 777-783
36 Clark AL. Clinical uses of intravenous immunoglobulin in pregnancy. Clin Obstet Gynecol 1999; 42: 368-380
37 Ballow M. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 1991; 68 (6 Suppl.): 1430-1436
38 Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012; 367: 2015-2025
39 Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994; 97 (Suppl. 01) 79-83
40 Cantú TG, Hoehn-Saric EW, Burgess KM. et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995; 25: 228-234
41 Katz U, Achiron A, Sherer Y. et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6: 257-259
42 Colpo A, Tison T, Gervasi MT. et al. Personalized treatment with immunoadsorption and intravenous immunoglobulin in a case of severe Rh alloimmunization during pregnancy unresponsive to plasma – exchange. Transfus Apher Sci 2017; 56: 480-483
43 Kamei K, Yamaguchi K, Sato M. et al. Successful treatment of severe rhesus D-incompatible pregnancy with repeated double-filtration plasmapheresis. J Clin Apher 2015; 30: 305-307
44 Hubinont C, Delens G, Vanalbada De Haan Hettema J. et al. Successful management of a severe anti-M alloimmunization during pregnancy. Eur J Obstet Gynecol Reprod Biol 2017; 217: 175-176
45 Tara F, Maleki A, Taheri N. et al. A case of D alloimmunization in pregnancy: successfully treated solely with therapeutic plasma exchange (TPE). J Blood Med 2019; 10: 251-253
46 Lin TH, Shih JC, Lin CH. et al. Intraperitoneal and intracardiac transfusion of recurrent fetal erythroblastosis due to anti-M alloimmunization with unfavorable outcome. Taiwan J Obstet Gynecol 2012; 51: 253-255